In glioblastoma, a combination of anti-TNFRSF18 and anti-PD-1 antibodies exhibited satisfactory survival benefits by targeting Tregs, indicating this may be a promising strategy for anti-tumor immunotherapy 45. This evidence concerns the gene PDCD1 and glioblastoma.